Trial reportAnesthesiology2013
Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain.
Trial report in Anesthesiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- Cancer-related pain: A bidirectional modulator of cancer progression.Clinical and translational medicine · 2026Review
- Interleukin receptor therapeutics attenuate inflammation in canine synovium following cruciate ligament injury.Osteoarthritis and cartilage · 2024Article
- Deep sequencing of Phox2a nuclei reveals five classes of anterolateral system neurons.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A perspective: neuraxial therapeutics in pain management: now and future.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.Communications biology · 2023Article
- Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.Toxins · 2022Review
- The Options for Neuraxial Drug Administration.CNS drugs · 2022Review
- Review
- The beneficial role of companion animals in translational pain research.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Advances in the interventional management of neuropathic pain.Annals of translational medicine · 2021Review
- Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.Frontiers in pharmacology · 2021Review
- Saporin fromToxins · 2020Review
- Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Anesthesia and analgesia · 2017Review
- Review
- Review
- Article
- Current and Future Issues in the Development of Spinal Agents for the Management of Pain.Current neuropharmacology · 2017Review
- Resiniferatoxin: The Evolution of the "Molecular Scalpel" for Chronic Pain Relief.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Role of neurokinin type 1 receptor in nociception at the periphery and the spinal level in the rat.Spinal cord · 2016Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 3 countries.
Funding
Abstract
backgroundSubstance P-saporin (SP-SAP), a chemical conjugate of substance P and a recombinant version of the ribosome-inactivating protein, saporin, when administered intrathecally, acts as a targeted neurotoxin producing selective destruction of superficial neurokinin-1 receptor-bearing cells in the spinal dorsal horn. The goal of this study was to provide proof-of-concept data that a single intrathecal injection of SP-SAP could safely provide effective pain relief in spontaneous bone cancer pain in companion (pet) dogs.
methodsIn a single-blind, controlled study, 70 companion dogs with bone cancer pain were randomized to standard-of-care analgesic therapy alone (control, n=35) or intrathecal SP-SAP (20-60 µg) in addition to standard-of-care analgesic therapy (n=35). Activity, pain scores, and videography data were collected at baseline, 2 weeks postrandomization, and then monthly until death.
resultsAlthough the efficacy results at the 2-week postrandomization point were equivocal, the outcomes evaluated beyond 2 weeks revealed a positive effect of SP-SAP on chronic pain management. Significantly, more dogs in the control group (74%) required unblinding and adjustment in analgesic protocol or euthanasia within 6 weeks of randomization than dogs that were treated with SP-SAP (24%; P<0.001); and overall, dogs in the control group required unblinding significantly sooner than dogs that had been treated with SP-SAP (P<0.01).
conclusionIntrathecal administration of SP-SAP in dogs with bone cancer produces a time-dependent antinociceptive effect with no evidence of development of deafferentation pain syndrome which can be seen with neurolytic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.